| Symbol | BTAI |
|---|---|
| Name | BIOXCEL THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 555 LONG WHARF DRIVE,12TH FLOOR, NEW HAVEN, Connecticut, 06511, United States |
| Telephone | +1 475 238-6837 |
| Fax | — |
| — | |
| Website | https://www.bioxceltherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001720893 |
| Description | BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501, and BXCL701. Additional info from NASDAQ: |
2026-07-06 10:00
(99% Neutral) BIOXCEL THERAPEUTICS, INC. (BTAI) Announces Business Combination
Read more
2026-06-18 00:01
Rodriguez Javier 🟡 adjusted position in 0 shares (1 derivative) of BioXcel Therapeutics, Inc. (BTAI) Transaction Date: Jun 15, 2026 | Filing ID: 075302
Read more
2026-06-18 00:00
Steinhart Richard I 🟡 adjusted position in 0 shares (1 derivative) of BioXcel Therapeutics, Inc. (BTAI) Transaction Date: Jun 15, 2026 | Filing ID: 075301
Read more
2026-06-18 00:00
Yocca Frank 🟡 adjusted position in 0 shares (1 derivative) of BioXcel Therapeutics, Inc. (BTAI) Transaction Date: Jun 15, 2026 | Filing ID: 075300
Read more
2026-06-18 00:00
Director Mehta Vimal 🟡 adjusted position in 0 shares (1 derivative) of BioXcel Therapeutics, Inc. (BTAI) Transaction Date: Jun 15, 2026 | Filing ID: 075298
Read more
2026-05-22 23:02
Yocca Frank 🟡 adjusted position in 6.8K shares (1 derivative) of BioXcel Therapeutics, Inc. (BTAI) at $1.08 Transaction Date: May 04, 2026 | Filing ID: 065841
Read more
2026-05-22 23:02
Rodriguez Javier 🟡 adjusted position in 6.6K shares (1 derivative) of BioXcel Therapeutics, Inc. (BTAI) at $1.08 Transaction Date: May 04, 2026 | Filing ID: 065839
Read more
2026-05-22 23:01
Steinhart Richard I 🟡 adjusted position in 6.8K shares (1 derivative) of BioXcel Therapeutics, Inc. (BTAI) at $1.08 Transaction Date: May 04, 2026 | Filing ID: 065838
Read more
2026-05-22 23:00
Director Mehta Vimal 🟡 adjusted position in 19.4K shares (1 derivative) of BioXcel Therapeutics, Inc. (BTAI) at $1.09 Transaction Date: May 04, 2026 | Filing ID: 065836
Read more
2026-05-20 20:29
📋 Mehta Vimal (Officer) plans to sell 19K shares of BioXcel Therapeutics, Inc. (at $1.09 each, total $21K) Filed: May 20, 2026 | ID: 000255
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06335407 | Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL50… | Phase1 | Alcohol Use Disorder (AUD) | Recruiting | 2025-07-28 | 2026-05-31 | ClinicalTrials.gov |
| NCT07116694 | Assessment of Acute Psychomotor Agitation Measures Associated With Schizophreni… | Phase2 | Bipolar I Disorder | Completed | 2025-06-19 | 2025-10-07 | ClinicalTrials.gov |
| NCT06041646 | Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation… | Phase4 | Bipolar Disorder | Completed | 2023-10-02 | 2024-04-29 | ClinicalTrials.gov |
| NCT05558982 | BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenoca… | Phase2 | Metastatic Pancreatic Ductal Adenocarcinoma | Active_Not_Recruiting | 2023-08-16 | 2027-11-01 | ClinicalTrials.gov |
| NCT06093451 | Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpat… | Phase4 | Schizophrenia Agitation | Unknown | 2023-07-01 | 2024-07-01 | ClinicalTrials.gov |
| NCT05712707 | Sublingual Dexmedetomidine for Treating Opioid Withdrawal | Phase1 | Opioid Use Disorder | Active_Not_Recruiting | 2023-02-28 | 2026-08-31 | ClinicalTrials.gov |
| NCT05665088 | Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUI… | Phase3 | Agitation | Terminated | 2022-12-14 | 2023-09-11 | ClinicalTrials.gov |
| NCT05658510 | Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and… | Phase3 | Agitation,Psychomotor | Completed | 2022-11-21 | 2025-08-15 | ClinicalTrials.gov |
| NCT05271552 | Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUI… | Phase3 | Agitation | Completed | 2022-04-27 | 2023-04-21 | ClinicalTrials.gov |
| NCT05276830 | An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associa… | Phase2 | Agitation | Terminated | 2022-02-08 | 2022-04-01 | ClinicalTrials.gov |
| NCT04827056 | Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) - Alcohol Int… | Phase1 | Alcohol Use Disorder (AUD) | Completed | 2021-11-09 | 2023-06-02 | ClinicalTrials.gov |
| NCT05025605 | Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatr… | Phase1 | Schizophrenia | Recruiting | 2021-08-27 | 2027-12-31 | ClinicalTrials.gov |
| NCT05313386 | Study of BXCL501 In Agitation Associated With Delirium in ICU Patients | Phase2 | Agitation | Withdrawn | 2021-02-23 | 2022-02-21 | ClinicalTrials.gov |
| NCT04470050 | Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal | Phase1 | Opioid Withdrawal | Completed | 2020-06-09 | 2021-02-18 | ClinicalTrials.gov |
| NCT04382170 | Dexmedetomidine Sublingual Film for the Management of Agitation in Delirium: Sa… | Phase2 | Delirium | Withdrawn | 2020-06-01 | 2021-06-01 | ClinicalTrials.gov |
| NCT04276883 | Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder | Phase3 | Agitation Associated With Bipolar Disorder | Completed | 2020-02-24 | 2020-05-21 | ClinicalTrials.gov |
| NCT04268303 | Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia | Phase3 | Agitation | Completed | 2020-01-24 | 2020-05-06 | ClinicalTrials.gov |
| NCT04390152 | Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cel… | Phase1 | Acute Respiratory Distress Syndrome | Terminated | 2020-01-13 | 2022-03-03 | ClinicalTrials.gov |
| NCT04251910 | Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia | Phase1 | Agitation,Psychomotor | Completed | 2019-12-27 | 2022-01-24 | ClinicalTrials.gov |
| NCT04123574 | A Pilot Study of BXCL701 in Patients With Pancreatic Cancer | Early_Phase1 | Cancer of Pancreas | Withdrawn | 2019-10-15 | 2021-12-06 | ClinicalTrials.gov |
| NCT04010305 | Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia | Phase1 | Agitation | Completed | 2019-05-22 | 2019-07-31 | ClinicalTrials.gov |
| NCT03910660 | A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell N… | Phase1 | Prostate Cancer | Completed | 2019-02-12 | 2025-08-31 | ClinicalTrials.gov |
Total clinical trials: 22
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo Film | Other | Phase PHASE3 | Agitation Associated With Bipolar Disorder | COMPLETED | NCT04276883 |
| Sublingual film containing Dexmedetomidine (BXCL501) | Other | Phase PHASE3 | Agitation Associated With Bipolar Disorder | COMPLETED | NCT04276883 |
| Placebo Film | Other | Phase PHASE3 | Agitation | COMPLETED | NCT04268303 |
| Sublingual film containing dexmedetomidine (BXCL501) | Other | Phase PHASE3 | Agitation | COMPLETED | NCT04268303 |
| Placebo | Other | Phase PHASE1 | Opioid Withdrawal | COMPLETED | NCT04470050 |
| Dexmedetomidine | Other | Phase PHASE1 | Opioid Withdrawal | COMPLETED | NCT04470050 |
| Placebo film | Other | Phase PHASE2 | Agitation | TERMINATED | NCT05276830 |
| BXCL501 | Other | Phase PHASE2 | Agitation | TERMINATED | NCT05276830 |
| Sublingual Placebo Film | Other | Phase PHASE1 | Agitation,Psychomotor | COMPLETED | NCT04251910 |
| Sublingual film containing Dexmedetomidine | Other | Phase PHASE1 | Agitation,Psychomotor | COMPLETED | NCT04251910 |
| BXCL701 monotherapy | Drug | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT03910660 |
| BXCL701 plus Pembrolizumab | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT03910660 |
| BXCL701 monotherapy | Drug | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT03910660 |
| BXCL701 plus Pembrolizumab | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT03910660 |
| BXCL701 monotherapy | Drug | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT03910660 |
| BXCL701 plus Pembrolizumab | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT03910660 |
| BXCL701 monotherapy | Drug | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT03910660 |
| BXCL701 plus Pembrolizumab | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT03910660 |
| BXCL701 monotherapy | Drug | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT03910660 |
| BXCL701 plus Pembrolizumab | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT03910660 |
| BXCL701 monotherapy | Drug | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT03910660 |
| BXCL701 plus Pembrolizumab | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT03910660 |
| BXCL701 monotherapy | Drug | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT03910660 |
| BXCL701 plus Pembrolizumab | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT03910660 |
| BXCL701 monotherapy | Drug | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT03910660 |
| BXCL701 plus Pembrolizumab | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT03910660 |
| Talabostat Mesylate | Other | Phase EARLY_PHASE1 | Cancer of Pancreas | WITHDRAWN | NCT04123574 |
| Placebo film | Other | Phase PHASE2 | Agitation | WITHDRAWN | NCT05313386 |
| BXCL501 | Other | Phase PHASE2 | Agitation | WITHDRAWN | NCT05313386 |
| Placebo film | Other | Phase PHASE1 | Agitation | COMPLETED | NCT04010305 |
| Sublingual film containing BXCL501 (Dexmedetomidine) | Other | Phase PHASE1 | Agitation | COMPLETED | NCT04010305 |
| Placebo Film | Other | Phase PHASE3 | Agitation | COMPLETED | NCT04268303 |
| Sublingual film containing dexmedetomidine (BXCL501) | Other | Phase PHASE3 | Agitation | COMPLETED | NCT04268303 |
| Placebo film | Other | Phase PHASE2 | Agitation | TERMINATED | NCT05276830 |
| BXCL501 | Other | Phase PHASE2 | Agitation | TERMINATED | NCT05276830 |
| Placebo Film | Other | Phase PHASE3 | Agitation Associated With Bipolar Disorder | COMPLETED | NCT04276883 |
| Sublingual film containing Dexmedetomidine (BXCL501) | Other | Phase PHASE3 | Agitation Associated With Bipolar Disorder | COMPLETED | NCT04276883 |
| Sublingual Placebo Film | Other | Phase PHASE1 | Agitation,Psychomotor | COMPLETED | NCT04251910 |
| Sublingual film containing Dexmedetomidine | Other | Phase PHASE1 | Agitation,Psychomotor | COMPLETED | NCT04251910 |
| Lorazepam 2 MG/ML | Other | Phase PHASE4 | Schizophrenia Agitation | UNKNOWN | NCT06093451 |
| Dexmedetomidine | Other | Phase PHASE4 | Schizophrenia Agitation | UNKNOWN | NCT06093451 |
| Alcohol Cue Reactivity | Other | Phase PHASE1 | Alcohol Use Disorder (AUD) | COMPLETED | NCT04827056 |
| PTSD Reactivity Condition | Other | Phase PHASE1 | Alcohol Use Disorder (AUD) | COMPLETED | NCT04827056 |
| Ethanol Infusion | Other | Phase PHASE1 | Alcohol Use Disorder (AUD) | COMPLETED | NCT04827056 |
| Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg | Other | Phase PHASE1 | Alcohol Use Disorder (AUD) | COMPLETED | NCT04827056 |
| Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg | Other | Phase PHASE1 | Alcohol Use Disorder (AUD) | COMPLETED | NCT04827056 |
| Placebo | Other | Phase PHASE1 | Alcohol Use Disorder (AUD) | COMPLETED | NCT04827056 |
| Placebo | Other | Phase PHASE1 | Opioid Withdrawal | COMPLETED | NCT04470050 |
| Dexmedetomidine | Other | Phase PHASE1 | Opioid Withdrawal | COMPLETED | NCT04470050 |
| Matching Placebo | Other | Phase PHASE3 | Agitation | TERMINATED | NCT05665088 |
| BXCL501 | Other | Phase PHASE3 | Agitation | TERMINATED | NCT05665088 |
| Dexmedetomidine sublingual film | Other | Phase PHASE2 | Delirium | WITHDRAWN | NCT04382170 |
| Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy) | Drug | Phase PHASE1 | Acute Respiratory Distress Syndrome | TERMINATED | NCT04390152 |
| Wharton's jelly derived Mesenchymal stem cells. | Other | Phase PHASE1 | Acute Respiratory Distress Syndrome | TERMINATED | NCT04390152 |
| Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy) | Drug | Phase PHASE1 | Acute Respiratory Distress Syndrome | TERMINATED | NCT04390152 |
| Wharton's jelly derived Mesenchymal stem cells. | Other | Phase PHASE1 | Acute Respiratory Distress Syndrome | TERMINATED | NCT04390152 |
| Matching Placebo | Other | Phase PHASE3 | Agitation,Psychomotor | COMPLETED | NCT05658510 |
| BXCL501 | Other | Phase PHASE3 | Agitation,Psychomotor | COMPLETED | NCT05658510 |
| BXCL701 monotherapy | Drug | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT03910660 |
| BXCL701 plus Pembrolizumab | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT03910660 |
| Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg | Other | Phase PHASE1 | Alcohol Use Disorder (AUD) | RECRUITING | NCT06335407 |
| Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg | Other | Phase PHASE1 | Alcohol Use Disorder (AUD) | RECRUITING | NCT06335407 |
| Matching Placebo | Other | Phase PHASE3 | Agitation | COMPLETED | NCT05271552 |
| BXCL501 | Other | Phase PHASE3 | Agitation | COMPLETED | NCT05271552 |
| Sublingual film containing Igalmi | Other | Phase PHASE4 | Bipolar Disorder | COMPLETED | NCT06041646 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05558982 |
| BXCL701 | Other | Phase PHASE2 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05558982 |
| BXCL501 Sublingual Film | Other | Phase PHASE2 | Bipolar I Disorder | COMPLETED | NCT07116694 |
| BXCL501 60 Micrograms | Other | Phase PHASE1 | Schizophrenia | RECRUITING | NCT05025605 |
| BXCL501 120 Micrograms | Other | Phase PHASE1 | Schizophrenia | RECRUITING | NCT05025605 |
| Placebo Film | Other | Phase PHASE1 | Schizophrenia | RECRUITING | NCT05025605 |
| BXCL501 80 Micrograms | Other | Phase PHASE1 | Schizophrenia | RECRUITING | NCT05025605 |
| Lofexidine (Positive Control) | Other | Phase PHASE1 | Opioid Use Disorder | ACTIVE_NOT_RECRUITING | NCT05712707 |
| Placebo | Other | Phase PHASE1 | Opioid Use Disorder | ACTIVE_NOT_RECRUITING | NCT05712707 |
| BXCL501 (240 micrograms) | Other | Phase PHASE1 | Opioid Use Disorder | ACTIVE_NOT_RECRUITING | NCT05712707 |
| BXCL501 (180 micrograms) | Other | Phase PHASE1 | Opioid Use Disorder | ACTIVE_NOT_RECRUITING | NCT05712707 |
| BXCL501 Sublingual Film | DRUG | Phase PHASE2 | Bipolar I Disorder | COMPLETED | NCT07116694 |
| Lorazepam 2 MG/ML | DRUG | Phase PHASE4 | Schizophrenia Agitation | RECRUITING | NCT06093451 |
| Sublingual film containing Igalmi | DRUG | Phase PHASE4 | Bipolar Disorder | COMPLETED | NCT06041646 |
| Lofexidine (Positive Control) | OTHER | Phase PHASE1 | Opioid Use Disorder | ACTIVE_NOT_RECRUITING | NCT05712707 |
| BXCL501 (240 micrograms) | DRUG | Phase PHASE1 | Opioid Use Disorder | ACTIVE_NOT_RECRUITING | NCT05712707 |
| BXCL501 (180 micrograms) | DRUG | Phase PHASE1 | Opioid Use Disorder | ACTIVE_NOT_RECRUITING | NCT05712707 |
| Pembrolizumab | DRUG | Phase PHASE2 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05558982 |
| BXCL701 | DRUG | Phase PHASE2 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05558982 |
| Matching Placebo | DRUG | Phase PHASE3 | Agitation | TERMINATED | NCT05665088 |
| BXCL501 | DRUG | Phase PHASE3 | Agitation | TERMINATED | NCT05665088 |
| BXCL501 60 Micrograms | DRUG | Phase PHASE1 | Schizophrenia | RECRUITING | NCT05025605 |
| BXCL501 120 Micrograms | DRUG | Phase PHASE1 | Schizophrenia | RECRUITING | NCT05025605 |
| BXCL501 80 Micrograms | DRUG | Phase PHASE1 | Schizophrenia | RECRUITING | NCT05025605 |
| Alcohol Cue Reactivity | BEHAVIORAL | Phase PHASE1 | Alcohol Use Disorder (AUD) | COMPLETED | NCT04827056 |
| PTSD Reactivity Condition | BEHAVIORAL | Phase PHASE1 | Alcohol Use Disorder (AUD) | COMPLETED | NCT04827056 |
| Ethanol Infusion | PROCEDURE | Phase PHASE1 | Alcohol Use Disorder (AUD) | COMPLETED | NCT04827056 |
| Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg | DRUG | Phase PHASE1 | Alcohol Use Disorder (AUD) | RECRUITING | NCT06335407 |
| Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg | DRUG | Phase PHASE1 | Alcohol Use Disorder (AUD) | RECRUITING | NCT06335407 |
| Placebo | OTHER | Phase PHASE1 | Opioid Use Disorder | ACTIVE_NOT_RECRUITING | NCT05712707 |
| Dexmedetomidine | DRUG | Phase PHASE4 | Schizophrenia Agitation | RECRUITING | NCT06093451 |
| Dexmedetomidine sublingual film | DRUG | Phase PHASE2 | Delirium | WITHDRAWN | NCT04382170 |
| Sublingual film containing Dexmedetomidine (BXCL501) | DRUG | Phase PHASE3 | Agitation Associated With Bipolar Disorder | COMPLETED | NCT04276883 |
| Placebo Film | DRUG | Phase PHASE1 | Schizophrenia | RECRUITING | NCT05025605 |
| Sublingual film containing dexmedetomidine (BXCL501) | DRUG | Phase PHASE3 | Agitation | COMPLETED | NCT04268303 |
| Sublingual Placebo Film | DRUG | Phase PHASE1 | Agitation,Psychomotor | COMPLETED | NCT04251910 |
| Sublingual film containing Dexmedetomidine | DRUG | Phase PHASE1 | Agitation,Psychomotor | COMPLETED | NCT04251910 |
| Talabostat Mesylate | DRUG | Phase EARLY_PHASE1 | Cancer of Pancreas | WITHDRAWN | NCT04123574 |
| Placebo film | DRUG | Phase PHASE2 | Agitation | WITHDRAWN | NCT05313386 |
| Sublingual film containing BXCL501 (Dexmedetomidine) | DRUG | Phase PHASE1 | Agitation | COMPLETED | NCT04010305 |
| BXCL701 monotherapy | DRUG | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT03910660 |
| BXCL701 plus Pembrolizumab | DRUG | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT03910660 |
Total products: 107